Regulators in several countries (e.g., Australia's Therapeutic Goods Administration) have updated safety warnings to include possible mood changes and suicidal thoughts/behavior with GLP-1 agonist drugs such as semaglutide (brand names Ozempic, Wegovy, etc.).https://www.giantrawsource.com/peptides/peptides-powder-semaglutide.html
These warnings stress that people taking these medicines should monitor and report new or worsening depression or unusual mood change.
Health updates posted by the FDA and safety groups have noted that serious breathing complications have been observed in some patients treated with GLP-1 receptor agonists (a class that includes semaglutide).
This represents another area of emerging safety information, especially for people with underlying respiratory conditions. MedShadow Foundation.
Although not a pharmacological warning, the FDA and FBI have issued warnings about counterfeit semaglutide products circulating in supply chains. These fake products can be unsafe, mislabeled, contaminated, or missing the active drug entirely - posing serious health risks if used.
